U
ATHE

UBS’s Alterity Therapeutics ATHE Stock Holding History

UBS’s Portfolio ATHE Stock Details ATHE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-230
Closed -$39K – 10396
2014
Q1 		$39K Buy
230
+85
+59% +$47K ﹤0.01% 7166
2013
Q4 		$61K Buy
+145
New +$43.4K ﹤0.01% 6695

Other funds holding ATHE

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
GBA
Garrison Bradford & Associates New York $88.4M AUM 15.86% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return
CAM
Columbia Asset Management Ann Arbor, Michigan $575M AUM 29.81% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
AG
Aperio Group Sausalito, California $33.8B AUM 31.46% 1-Year Est. Return

UBS's ATHE Position: Q3 2014 in Review

UBS reduced its Alterity Therapeutics (ATHE) stake by 96% in Q3 2014, selling an estimated $18.5K and leaving 6 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #10130.

UBS first reported a position in ATHE in Q3 2013 and has held it in 5 quarters since. The position peaked at $35K in Q4 2013. 26 funds tracked by Wall St. Rank hold ATHE as of Q3 2014.

  • UBS held 6 shares of Alterity Therapeutics worth $1K as of Q3 2014.
  • UBS sold 138 Alterity Therapeutics shares in Q3 2014, an estimated $18.5K.
  • Alterity Therapeutics made up ﹤0.01% of UBS's portfolio in Q3 2014, its #10130 holding.
  • UBS first reported a position in Alterity Therapeutics in Q3 2013 and has held it in 5 quarters since.
  • UBS's Alterity Therapeutics position peaked at $35K in Q4 2013.
  • 26 funds tracked by Wall St. Rank held Alterity Therapeutics as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.